The differential cricRNA enrichment pathway to the mTOR signaling pathway, which can be regulated by the intestinal metabolite imipramine, activates p38-p62-mTORc1, which in turn inhibits the function of insulin receptor substrates, blocking the insulin receptor pathway and leading to insulin resistance. Here, MTOR is linked to Insulin resistance.